Previous therapy with at least radiotherapy and temozolomide No previous radiotherapy, chemotherapy or other brain tumor directed therapy other than corticosteroid therapy and surgery Patients must have no previous radiotherapy or chemotherapy other than corticosteroids Previous first line treatment with at least radiotherapy. day wash-out period from any previous chemotherapy, targeted therapy or radiotherapy, day washout period from previous immunotherapy Dispositioned to single modality photon radiotherapy (i.e. no chemotherapy or previous therapeutic intent surgery). Previous chest radiotherapy Previous first line therapy with at least radiotherapy Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy Previous extensive radiotherapy to the lung or liver during the last months prior to lymphodepletion regimen. Previous radiotherapy within months before study entry No chemotherapy or radiotherapy within the past days and patients must have recovered any acute toxicity associated with their most recent previous treatment Patients who received previous radiotherapy to the brain Previous radiotherapy to the lung or mediastinum Previous radiotherapy of the tumor bed (for ACC). Previous radiotherapy to the brain. Participants who have received any chemotherapy or radiotherapy for previous malignancy are not eligible Previous first line treatment with at least standard dose of radiotherapy (total dose >= Gy) and temozolomide Subjects must have recovered from all toxicity associated with previous chemotherapy,\n targeted therapy, or radiotherapy Previous radiotherapy to the lesion(s) of interest Previous radiotherapy (XRT) or chemotherapy Previous stereotactic or highly conformal radiotherapy within weeks before the start of dosing for this study. Note the stereotactic radiotherapy field must not have included the brain index lesion(s) Previous first line therapy with at least radiotherapy and temozolomide. Previous lung or mediastinal radiotherapy Previous first line treatment with at least standard dose of radiotherapy (total dose >= gray [Gy]) and temozolomide Any previous systemic chemotherapy for cancer or radiotherapy for cancer Previous radiotherapy within weeks of starting study therapy. Persistence of clinically relevant therapy related toxicity from previous chemo and/or radiotherapy Previous first line therapy with at least radiotherapy and temozolomide Previous whole brain radiotherapy Previous treatment with radiotherapy and temozolomide (Cohorts , b and only) Previous chemotherapy, radiotherapy of other treatment for PC Glioblastoma disease-specific concerns: Patients must not have received previous or concurrent radiotherapy to the brain No previous radiotherapy or chemotherapy other than corticosteroid therapy Persistence of toxicity from previous chemo and/or radiotherapy > grade Previous radiotherapy to the pelvis Previous whole brain radiotherapy (WBRT) Subjects who are currently receiving or have had previous hormonal, chemotherapy, or radiotherapy for prostate cancer Cancer diagnosis or received treatment (chemotherapy or radiotherapy) for malignancy within the previous months Previous brain radiotherapy No previous radiotherapy or systemic treatment for SCCHN